DaVita Inc. Balances Solid Q2 With Emerging Risks

DaVita Inc. ((DVA)) has held its Q2 earnings call. Read on for the main highlights of the call.

DaVita Inc.’s latest earnings call struck a cautiously optimistic tone, blending solid financial execution with emerging pressures. Management highlighted robust Q2 profits, strong cash generation, and clear clinical advances, yet also underscored rising costs, revenue-per-treatment pressure, and payer-mix headwinds that could constrain margin expansion over the next several years.

Solid Q2 Financial Results

DaVita reported adjusted operating income of $579 million in Q2 2026, with enterprise operating income up about 5% year over year. Adjusted EPS reached $4.02 and free cash flow came in at $256 million, reinforcing the company’s ability to fund growth and shareholder returns.

Treatment Volume Growth Accelerating

U.S. dialysis treatment volumes increased 56 basis points year over year in the quarter, outpacing earlier expectations. Management now expects 2026 treatment growth to land near the top end of its prior 25–50 basis point range, signaling healthier patient volume trends.

Guidance Reconfirmed

The company reaffirmed its full-year 2026 outlook, targeting midpoint adjusted operating income of $2.2 billion. Midpoint adjusted EPS remains at $14.65, with management calling for a $50–$100 million sequential operating income step-up from Q3 to Q4 driven in part by timing in its integrated kidney care business.

Clinical Progress — Phosphate Binder Transition

DaVita noted a successful transition of phosphate binders into the Medicare dialysis bundle, cutting reliance on over-the-counter options by more than half. Regulators reduced their phosphate binder spend estimate by nearly $500 million, which supports the economics of in-bundle management and underscores DaVita’s clinical execution.

Clinical Breakthrough — MOTheR Trial & Expanded HD

The MOTheR trial showed that expanded hemodialysis using medium cutoff dialyzers is non-inferior to HDF on key outcomes like all-cause mortality and major cardiovascular events. DaVita has secured supply through NIPRO and plans broad deployment of expanded HD without significant new capital, positioning it for potential long-term clinical and economic gains.

Capital Allocation and Balance Sheet Discipline

The company repurchased 2.2 million shares in Q2 and another 183,000 shares after quarter-end, bringing year-to-date buybacks to about $785 million. It also completed a $200 million minority investment in Elara Caring, while keeping leverage at 3.37x consolidated EBITDA, squarely within its 3.0–3.5x target range.

International and IKC Contributions

International operations delivered $25 million of adjusted operating income, in line with expectations. Integrated kidney care surprised to the upside, generating about $40 million more operating income than anticipated, and management expects roughly $20 million of full-year enterprise operating income uplift from each of International and IKC.

Operational Cost Leverage in Quarter

Patient care cost per treatment declined about $3 sequentially, reflecting operating leverage on labor and benefits from lower phosphate binder costs. DaVita narrowed its forecast for full-year total cost-per-treatment growth to 1.25%–2.25%, signaling improved cost control despite broader inflationary pressures.

Revenue Per Treatment Pressure

Revenue per treatment fell approximately $2 sequentially in Q2, even though year-to-date levels remain 3.6% above the first half of 2025. Management now expects full-year revenue-per-treatment growth of just 1%–2%, implying slightly negative performance in the second half versus the prior-year period.

Commercial Mix Headwind from ACA Dynamics

Declining enrollment under Affordable Care Act plans and changes in effectuation are eroding DaVita’s higher-paying commercial mix. The company anticipates roughly a $40 million earnings headwind in 2026 from these dynamics, with an additional $70 million impact expected in 2027 as the mix shift fully annualizes.

Elevated Patient Care Cost Growth Year-to-Date

Despite sequential improvements, patient care costs per treatment are more than 3% higher year to date versus the first half of 2025. This elevated cost growth is running ahead of DaVita’s full-year expectations and is limiting the margin benefit from volume gains and productivity improvements.

Higher G&A and Other Cost Pressures

U.S. dialysis G&A expenses increased $11 million sequentially and were about 10% higher year over year, weighing on operating leverage. While depreciation and amortization declined about $9 million, the uptick in overhead costs partially offset gains from lower patient care costs.

Operational Headwinds — Missed Treatments and Fresenius Pickup Lower

The quarter saw more missed treatments than expected and fewer new patients from closed Fresenius clinics than previously modeled. This reduced the anticipated volume pickup by about 5 basis points and partially offset mortality-driven volume gains, adding near-term noise to growth trends.

Regulatory / Payment Uncertainty

Management highlighted uncertainty around the proposed 2027 ESRD payment update, noting that the suggested base rate still trails industry cost trends. The final rule and pending adjustments to the bundle for phosphate binders could materially influence DaVita’s 2027 financials and reimbursement landscape.

Near-Term Financial Impact of Expanded HD Limited

While expanded HD is expected to be operationally feasible and already factored into 2026 guidance, DaVita does not expect a meaningful financial benefit in the near term. Management believes any economic uplift hinges on mortality improvements that are unlikely to be realized until around 2028, framing expanded HD as a long-term value driver.

Forward-Looking Guidance and Outlook

DaVita reiterated its 2026 guidance with adjusted operating income centered at $2.2 billion and adjusted EPS at $14.65, backed by strong Q2 results. The company targets treatment growth near the high end of its 25–50 basis point range in 2026, a longer-term growth goal of at least 2% by 2029, modest 1%–2% revenue-per-treatment growth, and disciplined capital deployment amid ACA-related and regulatory uncertainties.

DaVita’s earnings call painted a story of a company executing well financially and clinically while navigating a tougher reimbursement and cost environment. Investors will be watching how management balances volume growth, cost control, and capital returns against ACA mix erosion and regulatory risk as the company pursues margin stability and longer-term growth through 2029.